Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma

Fig. 2

Evaluation of the immune signature in the internal validation cohort, the entire Beijing cohort, and the external validation cohort. A heatmap of the identified four-gene-based immune signature with the corresponding discriminant scores (left panel), and receiver operating characteristic curves (ROC) for the performance of the immune signature (right panel) in the internal validation cohort (a), entire Beijing cohort (b), and external validation cohort (c). Distributions of the discriminant scores between pCRs and <pCRs in the internal validation cohort (d), entire Beijing cohort (e), and external validation cohort (f). **** represents P < 0.0001

Back to article page